Duration of dual antiplatelet therapy after coronary stenting: A review of the evidence

Gilles Montalescot, David Brieger, Anthony J. Dalby, Seung Jung Park, Roxana Mehran

Research output: Contribution to journalReview articlepeer-review

100 Scopus citations

Abstract

The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with apparently conflicting results. Although longer exposure associates with more bleeding complications, late stent thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of ST compared with the first-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the most recent studies.

Original languageEnglish
Pages (from-to)832-847
Number of pages16
JournalJournal of the American College of Cardiology
Volume66
Issue number7
DOIs
StatePublished - 18 Aug 2015
Externally publishedYes

Keywords

  • P2Y inhibitors
  • antiplatelet therapy
  • aspirin
  • coronary stent
  • drug-eluting stent

Fingerprint

Dive into the research topics of 'Duration of dual antiplatelet therapy after coronary stenting: A review of the evidence'. Together they form a unique fingerprint.

Cite this